2%, <18 7%, 18–24 26%, 25–44 28%, 45–64 38%, >65 Side effects: 96% memory problems 77% headache 51% muscle pain 7% post-ECT delirium 2% teeth injuries 1% concentration difficulty 3% no side effects ECT training provided by: 73% institutions Guidelines not mentioned TPR: 3.78 AvE: 8 C-ECT Inhibitors,research,lifescience,medical practiced Modified Devices: Thymatron or MECTA device 2% old brief-pulse constant current device Type: Brief pulse Placement: 46% UL 24% BL 22% UL and BL 3% BL only

Dosage: 70% stimulus titration 28% age based 2% fixed dose New Zealand (L) Ministry of Health, New Zealand (Ministry of Health 2006) Study: National health data from 21 district health boards in two periods (2003/04 and 2004/05). Time span: Two Inhibitors,research,lifescience,medical periods of one year Gender: 69% women (both periods) Age >65: 40% (2004/05) 38% (2003/04) Ethnicity (2004/05; 2003/04) Asian: 2%; 1% European:

85%; 84% Maori: 6%; 5% Pacific people: 7%; 2% Other: Inhibitors,research,lifescience,medical 17%; 8% Legal regulations not consented: 22% (2004/05) 24% (2003/04) TPR: 0.75 (both periods) AvE: 7 New Zealand (L) Ministry of Health, New Zealand (Ministry of Health 2005) Study: Audit of technical aspects and quality of ECT delivered by site visit. N= 20 (district health boards) sites visited, and 19 (95%) sites providing ECT Inhibitors,research,lifescience,medical N= 414 (approximately) patients and 3506 ECT administrations Date: September to November 2002 Time span: Two months Training: 10 (50%) had advanced training program Guidelines: All had some forms of ECT policy,

but variations Other: All had ECT teams All ECT prescribed only by senior medical officer All sites administered by consultant psychiatrists or trained/supervised registrar All anesthesia by consulting anesthesiologist or trained/supervised anesthetic registrar All sites had recovery ECT nurse, four sites with specially employed ECT co-ordinating Metalloexopeptidase nurse Rate: 92 ECT treatments Inhibitors,research,lifescience,medical per 100,000 people (in 2001–2002) AvE: 8 Modified Type: Brief-pulse wave Devices and monitoring: 18 brief pulse with EEG One without EEG monitoring Australia & New Zealand (L) O’Dea JF (O’Dea et al. 1991) Study: Questionnaire survey (11 items) to N= 130 psychiatric buy Trametinib hospitals and units. N= 96 responded (74% response rate) and 20 of 96 (21%) did not provide ECT and two insufficient N= 74 institutions providing ECT N= 915 patients ECT treated in survey period Date: 1989 Time span: Six months Diagnoses: Mentioned according to preference of choice of electrode placement, with depression as main indication. N= 577 patients (63%) commenced treatment with unilateral ECT.